Do you providecompanies with innovative solutions to improve supply chain efficiency?
In addition to our primary packaging for solid doses, unit dose packaging and secondary packaging services, we also provide integrated supply chain services, such as postponement packaging or late-stage customisation to help our customers cope with small-scale market requirements.
In June 2017, the FDA announced that it will delay the active enforcement of the Drug Supply Chain Security Act (DSCSA) for pharmaceutical manufacturers to November 2018 due to industry-wide concerns that many members of the pharmaceutical supply chain are behind in implementing serialization systems and processes.
The numbers are daunting – 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way of life that features excessive noise exposure.
The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just a decade earlier and is driven in part by the increasing complexity of clinical trials.
Interview & Whitepapers
News & Press Releases
Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib data for the treatment of pediatric and adult patients whose tumors harbor Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusions.
Envigo, a leading provider of nonclinical contract research services and research models, announced the appointment of Lynn Lewis to the position of Senior Vice President, Global Sales.
Bristol-Myers Squibb Company announced the companies have executed a global strategic development and commercialization collaboration for Nektar’s lead immuno-oncology program, NKTR-214.
AbbVie , a global biopharmaceutical company, and Voyager Therapeutics, Inc. , a clinical-stage gene therapy company announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US FDA has approved Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT).
The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations, titles and authors are as follows:
- 10 April 2018 - 11 April 2018
- The Hotel Brussels, Brussels
- 11 April 2018 - 13 April 2018
- National Exhibition and Convention Center,
- 02 May 2018 - 06 May 2018
- Barcelona, Spain
- 29 August 2018 - 31 August 2018
- Marina Bay Sands
- 11 June 2018 - 15 June 2018
- Frankfurt am Main
ADC Biotechnology (ADC Bio) announces that it is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing.
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT).
Inovio Pharmaceuticals, Inc. and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology.
Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.001) at month six.
Medigene AG announced that the German Senior Federal Authority "Paul-Ehrlich-Institute" (PEI) and the relevant ethics committee have approved the study design of the first planned Phase I/II clinical trial with its T cell receptor (TCR)-modified T cell therapy MDG1011.
Vertex Pharmaceuticals Inc announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery.
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
Senior executives in manufacturing operations within large global corporations have selected the Thermo Scientific InSight wireless cold storage monitoring solution as the winner of the 2017 Manufacturing Leaders’ Innovation Award.
SCHOTT AG and ARaymond Life are announcing that SCHOTT adaptiQ® vials and ARaymondlife RayDyLyo® plastic press-fit closures are confirmed as a Product Set for use with Vanrx Pharmasystems’ Aseptic Filling Workcells.
New from Watson-Marlow Fluid Technology Group (WMFTG) is the Flexicon PF7 peristaltic tabletop aseptic liquid filling machine optimised for operation in GMP regulated industries such as biotechnology, pharmaceutical and diagnostics.